Funded July 15, 2016 

Criteria updated October 30, 2018: Pembrolizumab for the treatment of patients with unresectable or metastatic melanoma regardless of BRAF status. Treatment should be in patients with good performance status who have stable brain metastases (if present), using 2 mg/kg dose every 3 weeks for maximum of 200 mg for 24 months or until disease progression, whichever occurs first. Patients who stop therapy prior to progression or completed 2 years of therapy retreatment as per studies may be considered for up to 1 year. Time limited for patients who failed on ipilimumab if started on ipilimumab prior to pembrolizumab listing date (July 2016). 

Funded June 1, 2016 

Unresectable stage III or stage IV metastatic melanoma in patients:
– Ipilimumab–naïve, regardless of BRAF V600 mutation status
– ECOG 0–1
– Adequate hepatic and renal function
– Access to a treatment centre with expertise to manage immune-mediated adverse reactions of pembrolizumab
– A BCCA “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment
– Patients are eligible to receive pembrolizumab, ipilimumab or nivolumab but not sequential use of these agents
– Repeat every 3 weeks until disease progression, unacceptable toxicity, or a maximum of 2 years of treatment 

Funded, May 30, 2016 

i) For the treatment of patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Patients with BRAF V600 mutation positive melanoma may have received prior BRAF inhibitor or MEK inhibitor.
ii) For the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab therapy and, if BRAF V600 mutation positive, following a BRAF or MEK inhibitor. Eligibility will be for patients who received ipilimumab prior to May 30, 2016.
iii) Patients are required to have an Eastern Cooperative Oncology Group performance status of 0 or 1. 

Funded, June 2, 2016 

For the treatment of unresectable or metastatic melanoma (stage III or IV) in patients who are naïve to ipilimumab (Yervoy™) treatment. Patients who are BRAF mutation positive may or may not have received BRAF mutation targeted therapy. Patients initiated on ipilimumab (Yervoy™) therapy prior to June 2, 2016, are eligible to receive pembrolizumab upon treatment failure or disease progression. Patients who are BRAF mutation positive must have also failed BRAF mutation targeted therapy. Treatment in either setting should be in patients with an ECOG performance status of 0 or 1 and stable brain metastases (if present). The funded dose is pembrolizumab 2 mg/kg intravenously every 3 weeks for 24 months or until disease progression, whichever occurs first. 

Funded, June 2, 2016
Treatment of patients with advanced melanoma (unresectable or metastatic melanoma) for the following indications:

– Patients who are naïve to ipilimumab treatment (patients with BRAF mutation positive may or may not have received BRAF targeted therapy).

– Patients who have failed ipilimumab and, if BRAF mutation positive, have also failed BRAF mutation therapy.

– Sequential use of ipilimumab (i.e. pembrolizumab first followed by ipilimumab) will not be funded.

– Treatment should be in patients with an ECOG performance status 0 or 1, and who have stable brain metastases (if present).

– Duration of therapy will be 24 months or until disease progression, whichever occurs first. 

Funded, June 2, 2016 

As a single agent treatment option for patients with advanced melanoma (unresectable or metastatic melanoma) for the following indications: Ipilimumab– naïve: Patients who are naïve to ipilimumab treatment (patients with BRAF mutation positive may or may not have received BRAF targeted therapy).
OR Progression Post Ipilimumab (legacy patients only*): Patients who have failed ipilimumab and if BRAF mutation positive have also failed BRAF mutation therapy.(*pertains to eligible patients prior to funding of pembrolizumab). Patients in either setting should have an ECOG PS 0 or 1 and if present stable brain metastases.
Treatment duration in either patient population can continue for 24 months or until disease progression, whichever comes first.
Sequencing of anti-CTLA-4 immunotherapy agents (e.g. ipilimumab) post PD-1 inhibitors is not funded. 

Funded, June 2, 2016
For the treatment of patients with advanced melanoma (unresectable or metastatic melanoma) for the following:  

– Patients who are naive to ipilimumab treatment (patients with BRAF mutation positive may or may not have received BRAF targeted therapy).  

– Patients who have failed ipilimumab,*, and if BRAF mutation positive, have also failed BRAF mutation therapy.  

– Treatment in either setting should be in patients with an ECOG performance status of 0 or 1, and who have stable brain metastasis. *Patients who have received ipilimumab before the effective funding date of pembrolizumab will be eligible to receive pembrolizumab upon disease progression. Sequential use of ipilimumab (e.g., pembrolizumab first followed by ipilimumab) will not be publicly funded. 

Funded, September 1, 2016
Treatment of patients with advanced (unresectable or metastatic) melanoma as a single agent at a dose of 2 mg/kg every 3 weeks for 24 months or until disease progression, whichever occurs first, with the following criteria:
•First line checkpoint inhibitor immunotherapy in patients naїve to iIpilimumab treatment (patients with BRAF mutation positive tumours may or may not have received BRAF targeted therapy)
•Treatment in either setting if for patients with an ECOG performance status of 0 or 1 and who have stable brain metastases (if present)
Note: Pembrolizumab is not funded for patients who have disease progression after Nivolumab. Re‐treatment with pembrolizumab is not funded.
•Not to be used sequentially with ipilimumab 

Funded May 20, 2016 

Treatment of patients with advanced (unresectable or metastatic) melanoma as a single agent at a dose of 2 mg/kg every 3 weeks for 24 months or until disease progression, according to the following criteria:

• First–line checkpoint inhibitor immunotherapy in patients naïve to ipilimumab treatment (patients with BRAF mutation positive tumours may or may not have received BRAF targeted therapy)
• After failure of ipilimumab (and may have also failed BRAF targeted therapy) only for patients who received iIpilimumab before the effective funding date of pembrolizumab (May 2016)
• Treatment in either setting is for patients with an ECOG performance status of 0 or 1, and who have stable brain metastases (if present)